ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,00%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
79,535
-0,85%
Bitcoin
102 556,22
1,53%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Avalo Therapeutics Inc (AVTX) Cours

Avalo Therapeutics Inc

Avalo Therapeutics Inc (AVTX)

Avantium NV
6,75
0,02
(0,30%)
Fermé 20 Janvier 10:00PM
Retardé de 15 minutes
6,75
0,0199
(0,30%)
Après les heures de négociation: 12:56AM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
6,75
Prix Achat
6,63
Prix Vente
7,05
Volume échangé
238 024
6,04 Fourchette du Jour 6,93
3,9501 Plage de 52 semaines 34,46
Cap du marché
70,159M
Clôture Veille
6,73
Ouverture
6,73
Dernière Transaction
228
@
6.75
(formt)
Dernière heure de transaction
Volume financier
US$ 1 550 592
VWAP
6,5144
Volume moyen (3 m)
98 727
Actions en circulation
10 393 954
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,97
Bénéfice par action (BPA)
-3,03
Chiffre d'affairess
1,92M
Bénéfice net
-31,54M

À propos de Avalo Therapeutics Inc

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing... Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.avalotx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Avalo Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker AVTX. Le dernier cours de clôture d'Avalo Therapeutics était de US$6,73. Au cours de la dernière année, les actions de Avalo Therapeutics ont été négociées dans une fourchette de prix de US$ 3,9501 à US$ 34,46.

Avalo Therapeutics compte actuellement 10 393 954 actions en circulation. La capitalisation boursière d'Avalo Therapeutics est de US$69,95 million. Avalo Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.97.

AVTX Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

13 Janvier 2025
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

03 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

02 Janvier 2025
Edgar (US Regulatory)

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation...

02 Janvier 2025
GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

31 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

05 Décembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

12 Novembre 2024
Edgar (US Regulatory)

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at...

12 Novembre 2024
GlobeNewswire Inc.

Avalo Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation...

11 Novembre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.16-2.315484804636.917.475.99734066.68127438CS
4-2.35-25.82417582429.19.815.991365848.26811931CS
12-6.94-50.693937180413.69165.99987279.90056782CS
26-5.3-43.983402489612.05165.99542639.91632713CS
522.0944.84978540774.6634.463.950120177917.66188274CS
156-230.85-97.1590909091237.61711.23.9501790846635.3285612CS
260-682.05-99.0200348432688.81711.23.9501705348939.29395669CS

AVTX - Frequently Asked Questions (FAQ)

What is the current Avalo Therapeutics share price?
The current share price of Avalo Therapeutics is US$ 6,75
How many Avalo Therapeutics shares are in issue?
Avalo Therapeutics has 10 393 954 shares in issue
What is the market cap of Avalo Therapeutics?
The market capitalisation of Avalo Therapeutics is USD 69,95M
What is the 1 year trading range for Avalo Therapeutics share price?
Avalo Therapeutics has traded in the range of US$ 3,9501 to US$ 34,46 during the past year
What is the PE ratio of Avalo Therapeutics?
The price to earnings ratio of Avalo Therapeutics is -0,97
What is the cash to sales ratio of Avalo Therapeutics?
The cash to sales ratio of Avalo Therapeutics is 15,83
What is the reporting currency for Avalo Therapeutics?
Avalo Therapeutics reports financial results in USD
What is the latest annual turnover for Avalo Therapeutics?
The latest annual turnover of Avalo Therapeutics is USD 1,92M
What is the latest annual profit for Avalo Therapeutics?
The latest annual profit of Avalo Therapeutics is USD -31,54M
What is the registered address of Avalo Therapeutics?
The registered address for Avalo Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Avalo Therapeutics website address?
The website address for Avalo Therapeutics is www.avalotx.com
Which industry sector does Avalo Therapeutics operate in?
Avalo Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BTCTBTC Digital Ltd
US$ 8,2697
(73,73%)
61,45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8,80
(62,36%)
18,63M
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
NUKKNukkleus Inc
US$ 29,97
(45,98%)
19,09M
GSITGSI Technology
US$ 3,97
(44,36%)
87,7M
DOGZDogness International Corporation
US$ 18,23
(-58,77%)
740,45k
ORKTOrangeKloud Technology Inc
US$ 3,02
(-24,88%)
21,08M
PMAXPowell Max Ltd
US$ 0,6364
(-23,31%)
4,17M
LGCBLinkage Global Inc
US$ 0,2876
(-22,27%)
890,66k
YYAIConnexa Sports Technologies Inc
US$ 0,8299
(-20,20%)
602,48k
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
GCTKGlucoTrack Inc
US$ 0,0852
(15,45%)
465,22M
RIMEAlgorhythm Holdings Inc
US$ 0,0406
(-4,02%)
387,23M
TGLTreasure Global Inc
US$ 0,2459
(14,75%)
267,1M
NVDANVIDIA Corporation
US$ 137,71
(3,10%)
201,4M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
AVTX
Avalo Therapeutics
COIN
PHRBTC
Phore
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés